Navigation Links
International study supports new standard of treatment for women with advanced ovarian cancer
Date:12/3/2008

Louisville, Ky. Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. The study, presented at the 12th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) in Bangkok in October, has a major impact on many countries where the new standard represents a more practical course of treatment.

The prospective study was presented by Professor Ignace B. Vergote of University Hospital Leuven, EU, on behalf of the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) and the National Cancer Institute Canada-Clinical Trial Group (NCIC-CTG).

A total of 718 patients from 60 institutions with advanced ovarian cancer were enrolled in the study. The women were randomized to receive either primary debulking surgery (PDS) prior to receiving six cycles of chemotherapy (329 patients as per protocol), or interval debulking surgery (IDS) performed after three of six cycles of neoadjuvant chemotherapy (339 patients as per protocol). The current treatment guidelines for stage IIIc and IV disease recommend debulking surgery prior to administering chemotherapy. This study represents the first randomized phase III neoadjuvant clinical trial ever reported for ovarian cancer treatment.

"Most women diagnosed with ovarian cancer have advanced stage disease. Surgery before chemotherapy is not a practical course of treatment for patients in many countries because of difficulty scheduling surgery for patients with extensive cancer and associated complications," said the study's author, Prof. Vergote. "Because of this trend in treatment, our trial was designed to validate the administration of chemotherapy prior to surgery. In addition to establishing acceptability for this strategy, our study demonstrates fewer complications when chemotherapy is administered prior to surgery."

The median follow-up for all participants was 4.8 years. Overall survival and progression free survival were similar in both arms of the study, but a statistically significant reduction in complications, including postoperative deaths (2.7 percent in PDS versus .6 percent in IDS) was observed. The PDS arm of the study demonstrated a higher rate of hemorrhage (7 percent versus 1 percent) and blood clots (2.4 percent versus .3 percent).

"It was concluded that in patients with very extensive disease, as included in our study, neoadjuvant chemotherapy followed by interval debulking surgery can be considered as the preferred treatment. However, chemotherapy before surgery should not be used in patients with less than FIGO stage IIIc ovarian cancer, or small IIIc ovarian cancers, as these patients were not well-represented in the study" said Prof. Vergote. "Aggressive debulking surgery to no residual tumor remains the most important prognostic factor, underscoring the importance of a maximal surgical effort whenever the surgery is performed, whether the surgery is performed before or after chemotherapy."

Worldwide, nearly 200,000 women are diagnosed of ovarian cancer each year and every year, over 100,000 women die of the disease.


'/>"/>

Contact: Michael Bookman
michael.bookman@fccc.edu
215-728-2987
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified ... Surgery Journal , the official journal of The American Society for Aesthetic Plastic ... surgery. The procedure is designed to correct drooping, retracted lower eyelids, which usually ...
(Date:1/16/2017)... , ... January 16, 2017 , ... One thing common ... to treat, but to test for, as well. The money spent screening for and ... Doctors in the U.S. screen patients for cancer more than in any other country ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar ... Officer of the medical device company, effective immediately. , “This is perfect timing ... has a strong track record in medical device market development and revenue growth, ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... ... Supply, LLC is announcing the release of an updated version of their top selling ... edition has wide jaws that will accommodate nails up to 4mm in thickness . ... handle is reinforced for extra strength when pressing down on dense nails which can be ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 16, 2017   The Harrington Discovery Institute ... Ohio , has announced the 2017 recipients ... discoveries of physician-scientists whose research shows promise to ... Harrington Discovery Institute – part of The Harrington ... need in academic medicine: to advance early breakthroughs ...
(Date:1/16/2017)... According to the new market research report "Display Controller Market by ... LCD Controller), Application (Industrial Control, Medical Equipment, Automotive, Mobile Communication), and Geography ... to grow from USD 17.26 Billion in 2015 to reach USD 32.24 ... Continue Reading ... ...
(Date:1/16/2017)... 2017 The report "Cellulose ... (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), Application ... Coatings & Paints), Region - Global Forecast ... was valued at USD 4.51 Billion in ... 6.41 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: